1. New insights into 4-anilinoquinazolines as inhibitors of cardiac troponin I-interacting kinase (TNNI3K)
- Author
-
Christopher R. M. Asquith, Carrow I. Wells, Graham J. Tizzard, William J. Zuercher, and Tuomo Laitinen
- Subjects
4-anilino-quinazolines ,conformational flexibility ,Cardiac troponin ,Pharmaceutical Science ,Negative control ,Protein Serine-Threonine Kinases ,kinase inhibitor design ,01 natural sciences ,Analytical Chemistry ,lcsh:QD241-441 ,03 medical and health sciences ,chemistry.chemical_compound ,lcsh:Organic chemistry ,Drug Discovery ,Quinazoline ,Humans ,Myocytes, Cardiac ,Physical and Theoretical Chemistry ,Kinase activity ,Protein Kinase Inhibitors ,030304 developmental biology ,0303 health sciences ,Aniline Compounds ,010405 organic chemistry ,Kinase ,Communication ,Troponin I ,Organic Chemistry ,Small molecule ,0104 chemical sciences ,Biochemistry ,chemistry ,Chemistry (miscellaneous) ,Quinazolines ,Molecular Medicine ,CARDIAC TROPONIN I-INTERACTING KINASE ,cardiac troponin I–interacting kinase (TNNi3K) ,hinge binder ,Methyl group - Abstract
We report the synthesis of several related 4-anilinoquinazolines as inhibitors of cardiac troponin I–interacting kinase (TNNi3K). These close structural analogs of 3-((6,7-dimethoxyquinazolin-4-yl)amino)-4-(dimethylamino)-N-methylbenzenesulfonamide (GSK114) provide new understanding of structure–activity relationships between the 4-anilinoquinazoline scaffold and TNNi3K inhibition. Through a small focused library of inhibitors, we observed that the N-methylbenzenesulfonamide was driving the potency in addition to the more traditional quinazoline hinge-binding motif. We also identified a compound devoid of TNNi3K kinase activity due to the addition of a methyl group in the hinge binding region. This compound could serve as a negative control in the study of TNNi3K biology. Small molecule crystal structures of several quinazolines have been solved, supporting observations made about overall conformation and TNNi3K inhibition.
- Published
- 2020